Company intelligence / Profile preview

Guilin Huanuowei Gene Pharmaceutical

Guilin, Guangxi, China

Ownership: Private
Development stage: Other

Overview

Guilin Huanuowei Gene Pharmaceutical is a Chinese biotechnology company specializing in the development and manufacture of recombinant human genetic engineering drugs. Founded in 1993 and now a subsidiary of Guilin Sanjin Pharmaceutical, the company is best known for its flagship products, JinYinTi (rhEGF spray) and JinYinShu (rhEGF eye drops), which utilize recombinant human epidermal growth factor to promote tissue repair. These products are widely used in China for treating burns, chronic ulcers, and ophthalmic injuries. The company operates GMP-certified facilities and maintains a focus on biological wound healing and regenerative medicine.

Therapeutic areas: EndocrinologyOphthalmologyDermatology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Guilin Huanuowei Gene Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guilin Huanuowei Gene Pharmaceutical.

Explore the full profile